Left to right) Stav Cohen Adiv Mordechai & Dr. Avraham Ashkenazi. Researchers at Tel Aviv University discovered a new factor ...

With their help, we were able to identify a specific TMEM16F mutation which is common in Ashkenazi Jews in general ... new ...

The University of Pittsburgh was awarded $8 million to continue researching a new therapy for Parkinson's patients.

Common Degenerative Brain Disease May Begin to Develop in Middle ... In the future, the discovery may be used in treatment for Parkinson's ...

With rising demand and an ageing population, European healthcare systems are under strain. In the second article in our ...

Nir Giladi from TAU’s Faculty of Medical and Health Sciences and the Tel Aviv Sourasky Medical Center, as well as other researchers from TAU and the University of Haifa. The study was backed by the ...

Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's. It is the fastest growing condition of its type in the world and, although there are treatments to ...

This affordable and eco-friendly treatment could be available in pill ... functioning and could be life-threatening. The most ...

Early initiation of pimavanserin among patients with Parkinson disease psychosis were more likely to experience complete symptom resolution.

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

Can a common parasite help treat Alzheimer’s? Scientists say Toxoplasma gondii may open pathways to brain therapies for ...